Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf329 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Xi-Lin Yang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing …. Hauptthemen laut MEDLINE: Chemoradiotherapy, Uterine Cervical Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, Ministry of Science and Technology of the People’s Republic of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To compare the survival difference between 2018 International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer (CC) patients with unilateral parametrial invasion (UL) and bilateral parametrial invasion (BL) disease, and explore the significant role of parametrial invasion (PI) in prognosis prediction.
Methods
A total of 506 stage IIB CC patients were identified from the multi-center study, and patients were divided into UL and BL groups according to gynecological and radiological examination. Survival outcomes were estimated and compared between 2 groups before and after propensity scoring matching (PSM). The role of upper 2/3 vaginal invasion (VI) in impacting survival probability was also assessed. The random forest (RF) model was constructed and validated to select important features related to survival outcomes and predict prognosis for these patients. The SHapley Additive exPlanation (SHAP) was further introduced to provide a better understanding toward the findings from the RF model.
Results
Significant better 5-year overall survival (OS) was observed among patients with UL disease whether before (BL: 61.7% [95% CI: 57.0%-66.4%]; UL: 84.8% [95% CI: 82.4%-87.2%]; HR = 2.83, 95% CI: 1.90-4.20, P < 0.001) or after PSM (BL: 61.3% [95% CI: 56.6%-66.0%]; UL: 81.2% [95% CI: 77.3%-85.1%]; HR = 2.51, 95% CI: 1.56-4.04, P < 0.001). Similar findings could also be observed in terms of progression-free survival (PFS). The presence of VI didn’t significantly impair the survival probability, whether in the UL or BL group (all P > 0.05). RF model was constructed, which possessed decent predictive ability both in the training (area under the receiver operating characteristic curve [AUC] = 0.893; 95% CI: 0.874-0.912) and validation cohort (AUC = 0.879; 95% CI: 0.801-0.957). PI was identified to be the paramount feature in affecting the survival outcomes for stage IIB CC patients through the Beeswarm summary plot and bar chart in SHAP analysis.
Conclusion
Our findings demonstrated that 2018 FIGO stage IIB CC patients with BL disease had a worse prognosis than those with UL disease, and PI was the most significant feature in prognosis prediction for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 10000, China.
- Department of Radiation Oncology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 10000, China.
- Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi'an, Shanxi 710000, China.
- Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750000, China.
- Department of Radiation Oncology, The Second Affiliated Hospital of Jilin University, Changchun 130041, China.
- Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Gui Yang, GuiZhou 550004, China.
ORCID-Profile: Xi-Lin Yang, Fu-Quan Zhang
Förderung
- Ministry of Science and Technology of the People's Republic of China
- Ministry of Science and Technology of the People’s Republic of China
Zitieren
APA
Yang, X. L., Wei, L. C., He, J. L., Wang, T. J., Ran, L., Zou, L. J., Sun, X. G., Li, X. M., Liu, Z., Shi, Y. G., Li, S., Zhao, F. J., Gao, K., Zhong, W., Cheng, G. H., Gao, Y. L., Sun, B. S., Yan, J. F., & Zhang, F. Q. (2025). Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy. The Oncologist. https://doi.org/10.1093/oncolo/oyaf329
Vancouver
Yang XL, Wei LC, He JL, Wang TJ, Ran L, Zou LJ, et al. Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy. The Oncologist. 2025. doi:10.1093/oncolo/oyaf329
BibTeX
@article{Yang2025,
author = {Yang, Xi-Lin and Wei, Li-Chun and He, Jian-Li and Wang, Tie-Jun and Ran, Li and Zou, Li-Juan and Sun, Xiao-Ge and Li, Xiao-Mei and Liu, Zi and Shi, Yong-Gang and Li, Sha and Zhao, Feng-Ju and Gao, Kun and Zhong, Wei and Cheng, Guang-Hui and Gao, Ya-Li and Sun, Bao-Sheng and Yan, Jun-Fang and Zhang, Fu-Quan},
title = {Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf329}
}
EUVIMED